SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Apple Restores Telegram to App Store After Content Policy Violation 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
VANCOUVER, British Columbia, March 21, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 17th Annual Needham Healthcare Conference in New York on Wednesday, March 28th 2018.
Aquinox Presentation Details
Date: Wednesday, March 28th 2018
Time: 2:00 pm Eastern Time / 11:00 am Pacific Time
Location: New York, NY – Westin New York Grand Central
A live audio webcast and archive of the event will be available at:
http://wsw.com/webcast/needham86/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
